Efficient LAMA1 Gene Activation by Epigenome Editing as a Therapeutic Approach for LAMA2-CMD

Area of Science:

• Gene therapy
• Epigenetics
• Rare genetic diseases

Background:

• Congenital muscle dystrophy (CMD) is a severe genetic disorder.
• LAMA2-CMD is caused by mutations in the LAMA2 gene.
• LAMA1 gene can compensate for LAMA2 function, but direct gene therapy is challenging due to large coding sequences.

Purpose of the Study:

• To demonstrate epigenetic activation of the LAMA1 gene for LAMA2-CMD treatment.
• To develop a feasible therapeutic strategy bypassing large gene delivery limitations.

Main Methods:

• Utilized an adeno-associated virus (AAV) vector for epigenetic activation of LAMA1.
• Tested the AAV vector in mouse models of LAMA2-CMD.
• Evaluated vector biodistribution, pharmacodynamics, and safety in juvenile and infant nonhuman primates (NHPs).

Main Results:

• Significant LAMA1 gene upregulation and phenotype improvement observed in mouse models.
• Muscle-tropic AAV vector showed favorable biodistribution and pharmacodynamics in NHPs.
• Infant NHPs demonstrated superior pharmacodynamics compared to juvenile NHPs at a lower dose, with good safety profiles.

Conclusions:

• Epigenetic activation of LAMA1 is a viable therapeutic strategy for LAMA2-CMD.
• The AAV-based epigenome editing approach is applicable to various loss-of-function genetic disorders.
• This method offers a potential therapeutic breakthrough for genetic conditions benefiting from epigenetic modulation.